Association between liver insulin resistance and cardiovascular risk factors

Journal of Internal Medicine

Volumn 272, Issue 4, 2012, Pages 402-408

  Vangipurapu, J ^a   Stancakova A ^a   Kuulasmaa, T ^a   Soininen, P ^b,c   Kangas, A J ^b   Ala Korpela, M ^b,c   Kuusisto, J ^a   Laakso, M ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cardiovascular disease risk; Insulin resistance; Lipoproteins; Liver; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

CARDIOVASCULAR DISEASES; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84866329009     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02540.x     Document Type: Article

References (22)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
2. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38: 387-95.
3. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-9F.
4. Stančáková A, Kuulasmaa T, Paananen J et al. Association of 18 confirmed susceptibility loci for Type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5 327 non-diabetic Finnish men. Diabetes 2009; 58: 2129-36.
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29(Suppl. 1): S43-8.
6. Soininen P, Kangas AJ, Würtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5.
7. Okazaki M, Usui S, Ishigami M et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005; 25: 578-84.
8. Vangipurapu J, Stančáková A, Kuulasmaa T et al. A novel surrogate index for hepatic insulin resistance. Diabetologia 2011; 54: 540-3.
9. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
11. Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull 1980; 87: 245-51.
12. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
13. Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999; 286: 145-61.
14. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95: 158-66.
15. Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-62.
16. Krauss RM, Lindgren FT, Williams PT et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 330: 62-6.
17. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
18. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
19. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
20. Möhlig M, Wegewitz U, Osterhoff M et al. Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002; 34: 655-8.
21. Stefan N, Stumvoll M, Vozarova B et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26: 3315-9.
22. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.